CALL - SPRINTER OPEN END - BIOGEN IDEC | Market Closed - Deutsche Boerse AG 01:47:16 2024-07-12 pm EDT | ||
| 4.55 EUR | -15.11% |
|
| Current month | -8.27% | ||
| 1 month | -7.14% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 4.55 | -15.11% |
| 24-07-11 | 5.36 | +8.94% |
| 24-07-10 | 4.92 | +5.35% |
| 24-07-09 | 4.67 | +1.08% |
| 24-07-08 | 4.62 | +3.82% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 01:47 pm EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX8LN9 |
| ISIN | DE000VX8LN96 |
| Date issued | 2022-03-11 |
| Strike | 180.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.53 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.98 € |
|---|---|
| Lowest since issue | 1.36 € |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
230.1
USD
Average target price
281.3
USD
Spread / Average Target
+22.27%
- Stock Market
- Certificates
- Certificat
